Mei Li1, Zoran Popovic2, Chang Chu1,3, Bernhard K Krämer1,4,5, Berthold Hocher1,6,7. 1. Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany. 2. Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany. 3. Department of Nephrology, Charité, Universitätsmedizin Berlin, Berlin, Germany. 4. European Center for Angioscience, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. 5. Center for Innate Immunoscience, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. 6. Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, China. 7. Institute of Medical Diagnostics, IMD Berlin, Berlin, Germany.
Abstract
Endostatin, a protein derived from the cleavage of collagen XVIII by the action of proteases, is an endogenous inhibitor known for its ability to inhibit proliferation and migration of endothelial cells, angiogenesis, and tumor growth. Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature, which is crucial in many physiological processes, such as embryogenesis, tissue regeneration, and neoplasia. SUMMARY: Increasing evidence shows that dysregulation of angiogenesis is crucial for the pathogenesis of renal and cardiovascular diseases. Endostatin plays a pivotal role in the regulation of angiogenesis. Recent studies have provided evidence that circulating endostatin increases significantly in patients with kidney and heart failure and may also contribute to disease progression. KEY MESSAGE: In the current review, we summarize the latest findings on preclinical and clinical studies analyzing the impact of endostatin on renal and cardiovascular diseases.
Endostatin, a protein derived from the cleavage of collagen XVIII by the action of proteases, is an endogenous inhibitor known for its ability to inhibit proliferation and migration of endothelial cells, angiogenesis, and tumor growth. Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature, which is crucial in many physiological processes, such as embryogenesis, tissue regeneration, and neoplasia. SUMMARY: Increasing evidence shows that dysregulation of angiogenesis is crucial for the pathogenesis of renal and cardiovascular diseases. Endostatin plays a pivotal role in the regulation of angiogenesis. Recent studies have provided evidence that circulating endostatin increases significantly in patients with kidney and heart failure and may also contribute to disease progression. KEY MESSAGE: In the current review, we summarize the latest findings on preclinical and clinical studies analyzing the impact of endostatin on renal and cardiovascular diseases.
Authors: Chi Hua Sarah Lin; Jun Chen; Zhongtao Zhang; Gail V W Johnson; Arthur J L Cooper; Julianne Feola; Alexander Bank; Jonathan Shein; Heli J Ruotsalainen; Taina A Pihlajaniemi; Michael S Goligorsky Journal: Kidney Int Date: 2016-04-14 Impact factor: 10.612
Authors: Jing Chen; L Lee Hamm; Myra A Kleinpeter; Fred Husserl; Islam Enver Khan; Chung-Shiuan Chen; Yanxi Liu; Katherine T Mills; Chuan He; Nader Rifai; Eric E Simon; Jiang He Journal: Am J Nephrol Date: 2012-03-27 Impact factor: 3.754
Authors: M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman Journal: Cell Date: 1997-01-24 Impact factor: 41.582
Authors: Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2015-01-15 Impact factor: 21.405
Authors: Andriana Nikolova; Klemens Ablasser; Moritz C Wyler von Ballmoos; Dimitrios Poutias; Elisabeth Kaza; Francis X McGowan; Marsha A Moses; Pedro J Del Nido; Ingeborg Friehs Journal: Ann Thorac Surg Date: 2012-07-12 Impact factor: 4.330